- Home
- THRY vs OCS Comparison
THRY vs OCS Comparison
Compare THRY & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRY
- OCS
- Stock Information
- Founded
- THRY 2003
- OCS 2003
- Country
- THRY United States
- OCS Switzerland
- Employees
- THRY N/A
- OCS N/A
- Industry
- THRY Industrial Machinery/Components
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- THRY Industrials
- OCS Health Care
- Exchange
- THRY Nasdaq
- OCS Nasdaq
- Market Cap
- THRY 604.6M
- OCS 706.3M
- IPO Year
- THRY 2020
- OCS N/A
- Fundamental
- Price
- THRY $13.73
- OCS $14.14
- Analyst Decision
- THRY Strong Buy
- OCS Strong Buy
- Analyst Count
- THRY 3
- OCS 5
- Target Price
- THRY $24.33
- OCS $29.20
- AVG Volume (30 Days)
- THRY 747.4K
- OCS 73.4K
- Earning Date
- THRY 11-07-2024
- OCS 11-07-2024
- Dividend Yield
- THRY N/A
- OCS N/A
- EPS Growth
- THRY N/A
- OCS N/A
- EPS
- THRY N/A
- OCS N/A
- Revenue
- THRY $873,723,000.00
- OCS $1,027,571.00
- Revenue This Year
- THRY N/A
- OCS $4.38
- Revenue Next Year
- THRY N/A
- OCS $905.09
- P/E Ratio
- THRY N/A
- OCS N/A
- Revenue Growth
- THRY N/A
- OCS N/A
- 52 Week Low
- THRY $13.60
- OCS $9.60
- 52 Week High
- THRY $26.42
- OCS $18.00
- Technical
- Relative Strength Index (RSI)
- THRY 32.98
- OCS 37.01
- Support Level
- THRY $14.27
- OCS $16.44
- Resistance Level
- THRY $15.07
- OCS $18.00
- Average True Range (ATR)
- THRY 0.82
- OCS 0.68
- MACD
- THRY -0.15
- OCS -0.46
- Stochastic Oscillator
- THRY 2.61
- OCS 3.50
About THRY Thryv Holdings Inc.
Thryv Holdings Inc provides software as service (SaaS) management tools and digital and print marketing tools to small and mid-sized businesses. The company operates in four reportable segments namely Thryv U.S. Marketing Services, Thryv U.S. SaaS, Thryv International Marketing Services, and Thryv International SaaS. It generates maximum revenue from the Thryv U.S. Marketing Services segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.